Basel, June 2, 2020 -- Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency
has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab ...
Press Release: Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab …